Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Stomach Neoplasms 3Carcinoma, Non-Small-Cell Lung 2Solid Tumors 1Sarcoma, Synovial 1Sarcoma 1Non-small Cell Lung Cancer Metastatic 1Neoplasms by Site 1Neoplasms 1Mesothelioma, Malignant 1Gastrointestinal Neoplasms 1Digestive System Neoplasms 1Advanced Solid Tumor 1Adenocarcinoma Gastric 1Adenocarcinoma 1

Interventions

sargramostim 1sapanisertib 1pazopanib 1itacitinib 1fludarabine 1drozitumab 1baricitinib 1atezolizumab 1Trabectedin 1Ramucirumab 1Ipilimumab 1Interferon-gamma 1INCB039110 1Gemcitabine 1Doxorubicin 1Docetaxel 1Dehydroepiandrosterone 1Cyclophosphamide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma, Synovial × Ramucirumab × Clear all
NCT04145700 2023-09-13

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma

Eli Lilly and Company

Phase 1/2 Terminated
23 enrolled 15 charts
Sarcoma

Sarcoma, Sarcoma, Synovial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡